Francis Collins to head NIH

Dr. Francis Collins has been appointed to head the National Institutes of Health.

Abraxis BioScience announced the appointments of Mary Lynne Hedley, Ph.D. as executive vice president of operations and chief scientific officer and Rick Rodgers as senior vice president and chief financial officer.

Amgen has named Rebecca M. Henderson to the company's board of directors.

The Scripps Research Institute has appointed Scott Forrest as the institute's new director of business and technology development.

Mark Rolfe, Ph.D. has been appointed senior vice president and chief scientific officer of Facet Biotech.

MDRNA announced the appointment of Peter S. Garcia as chief financial officer and secretary.

Jeffrey Leiden, M.D., Ph.D. and Dennis Winger have joined Vertex Pharmaceuticals's board of directors.

Poniard Pharmaceuticals has elected Gary A. Lyons to the company's board of directors. 

Antares Pharma has promoted Robert F. Apple to executive vice president, chief financial officer and president of the Parenteral Products Division, Dr. Kaushik Dave to senior vice president of product development and Dr. Peter Sadowski to senior vice president of the Parenteral Products Division.

Geoffrey M. Parker has been named chief business officer of InteKrin Therapeutics.

OncoMed Pharmaceuticals has appointed Sunil Patel as senior vice president of corporate development.

Pro-Pharmaceuticals has named Dr. Gilbert S. Omenn to its scientific advisory board.

Jonathan Lieber has been appointed chief financial officer of Xcellerex. 

NPS Pharmaceuticals has appointed Colin Broom, M.D., to its board of directors.

Dicerna Pharmaceuticals has named David M. Madden as independent chairman of the company's board of directors.

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as vice president of administration and controller.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.